Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
WEC | <0.01% | $33.48B | +22.69% | 3.29% |
AWR | -0.07% | $3.00B | -1.24% | 2.34% |
ZH | 0.08% | $319.69M | +2.30% | 0.00% |
NUS | -0.11% | $369.12M | -46.10% | 3.20% |
ORLY | 0.14% | $78.08B | +36.20% | 0.00% |
KNDI | -0.15% | $106.62M | -44.64% | 0.00% |
SWBI | 0.16% | $428.59M | -39.84% | 5.35% |
BEKE | 0.20% | $22.08B | +0.10% | 1.90% |
T | 0.21% | $196.66B | +57.98% | 4.07% |
HLF | -0.21% | $720.06M | -36.19% | 0.00% |
TAK | -0.23% | $44.06B | +5.18% | 2.33% |
OXBR | 0.24% | $14.89M | +14.29% | 0.00% |
BBD | 0.27% | $14.48B | +13.42% | 1.47% |
BNED | 0.28% | $371.19M | -38.80% | 0.00% |
SOHU | 0.29% | $330.12M | -9.26% | 0.00% |
MED | 0.30% | $146.95M | -47.28% | 0.00% |
WTRG | -0.33% | $10.70B | -3.17% | 3.41% |
VIPS | -0.37% | $6.31B | -15.50% | 3.26% |
PTMN | 0.40% | - | - | 20.16% |
DUK | 0.44% | $90.12B | +12.74% | 3.61% |
Double maintains 2 strategies that include RYTM - Rhythm Pharmaceuticals, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -36.80% | $361.41M | 1.43% |
VIXY | -31.48% | $109.64M | 0.85% |
TAIL | -29.17% | $140.49M | 0.59% |
DFNM | -22.20% | $1.53B | 0.17% |
FMHI | -19.84% | $757.44M | 0.7% |
SHYD | -19.62% | $318.05M | 0.35% |
MMIT | -18.96% | $829.60M | 0.3% |
SMB | -18.94% | $269.10M | 0.07% |
NYF | -18.27% | $875.13M | 0.25% |
SMMU | -18.13% | $822.53M | 0.35% |
SHYM | -18.07% | $322.93M | 0.35% |
MLN | -18.06% | $532.71M | 0.24% |
SUB | -17.86% | $9.40B | 0.07% |
HYMB | -17.75% | $2.53B | 0.35% |
PZA | -17.52% | $2.89B | 0.28% |
JMST | -16.81% | $3.65B | 0.18% |
CMF | -16.66% | $3.57B | 0.08% |
CGSM | -16.60% | $658.61M | 0.25% |
TPMN | -16.56% | $31.54M | 0.65% |
HYD | -16.30% | $3.37B | 0.32% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -16.13% | $22.95B | +20.67% | 1.12% |
LITB | -14.97% | $21.28M | -72.45% | 0.00% |
AMT | -14.16% | $99.10B | +8.59% | 3.09% |
BCE | -13.89% | $19.94B | -37.01% | 13.15% |
ED | -12.04% | $36.75B | +5.26% | 3.28% |
GIS | -11.01% | $29.79B | -23.81% | 4.42% |
HIHO | -10.94% | $8.25M | -10.29% | 3.73% |
MKTX | -10.78% | $8.01B | -1.42% | 1.39% |
PEP | -10.29% | $180.30B | -28.19% | 4.14% |
TEF | -10.10% | $27.20B | +8.80% | 6.44% |
CL | -9.78% | $72.64B | -5.18% | 2.25% |
MO | -9.54% | $97.80B | +26.35% | 6.94% |
CI | -9.01% | $82.51B | -8.96% | 1.84% |
AEP | -8.74% | $54.28B | +9.80% | 3.61% |
JKHY | -8.63% | $13.15B | +6.64% | 1.23% |
PDD | -8.43% | $164.05B | -17.81% | 0.00% |
VZ | -7.87% | $183.32B | +8.02% | 6.21% |
CPB | -7.44% | $10.42B | -25.16% | 4.36% |
CAG | -7.42% | $10.87B | -26.52% | 6.17% |
TU | -7.30% | $23.77B | -4.62% | 7.19% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RCKT | 45.72% | $724.54M | -71.26% | 0.00% |
DNLI | 45.17% | $2.06B | -30.04% | 0.00% |
IDYA | 45.10% | $1.52B | -58.32% | 0.00% |
CRNX | 44.70% | $2.92B | -39.88% | 0.00% |
KYMR | 44.46% | $1.95B | -15.67% | 0.00% |
RVMD | 43.54% | $7.35B | +1.15% | 0.00% |
XENE | 43.06% | $2.27B | -26.70% | 0.00% |
SANM | 42.72% | $4.50B | +27.92% | 0.00% |
KN | 42.40% | $1.48B | -2.96% | 0.00% |
COHR | 41.40% | $12.25B | +35.13% | 0.00% |
MOG.A | 41.06% | $5.80B | +8.27% | 0.62% |
SYF | 40.76% | $23.03B | +39.12% | 1.74% |
TWST | 40.46% | $1.80B | -35.27% | 0.00% |
HPE | 40.24% | $23.15B | -1.51% | 2.95% |
APO | 40.22% | $82.29B | +27.73% | 1.29% |
EVR | 40.19% | $9.17B | +19.07% | 1.35% |
S | 39.72% | $6.63B | -9.25% | 0.00% |
ROIV | 39.69% | $7.68B | -5.70% | 0.00% |
KRYS | 39.60% | $3.77B | -20.42% | 0.00% |
GTLS | 39.24% | $7.78B | +10.62% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FTSM | -<0.01% | $6.54B | 0.45% |
GNMA | -0.05% | $355.60M | 0.1% |
USTB | 0.06% | $1.19B | 0.35% |
SCHZ | 0.08% | $8.47B | 0.03% |
BND | -0.10% | $125.46B | 0.03% |
DBA | -0.11% | $839.66M | 0.93% |
FIXD | 0.12% | $3.54B | 0.65% |
JBND | 0.16% | $1.92B | 0.25% |
FISR | -0.28% | $404.42M | 0.5% |
SUSB | -0.32% | $967.17M | 0.12% |
BIV | 0.34% | $22.85B | 0.03% |
FBND | 0.38% | $18.20B | 0.36% |
SHY | 0.38% | $24.03B | 0.15% |
JMBS | 0.39% | $5.40B | 0.22% |
BAB | -0.47% | $919.66M | 0.28% |
UCON | 0.56% | $3.06B | 0.85% |
GVI | -0.58% | $3.37B | 0.2% |
MINT | 0.60% | $13.18B | 0.35% |
FTXG | -0.60% | $34.98M | 0.6% |
CANE | 0.61% | $10.71M | 0.29% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PTH | 54.95% | $96.56M | 0.6% |
XBI | 53.27% | $4.85B | 0.35% |
ARKG | 48.61% | $944.78M | 0.75% |
IWO | 47.95% | $11.36B | 0.24% |
IWC | 47.57% | $766.88M | 0.6% |
GNOM | 47.35% | $40.65M | 0.5% |
IBB | 46.62% | $5.22B | 0.45% |
IWM | 45.81% | $63.95B | 0.19% |
VTWO | 45.67% | $12.07B | 0.07% |
QMOM | 45.10% | $302.83M | 0.29% |
IWMY | 44.81% | $109.62M | 1.02% |
CPRJ | 44.73% | $48.43M | 0.69% |
PINK | 44.05% | $131.52M | 0.5% |
ISCG | 43.59% | $645.00M | 0.06% |
VBK | 43.57% | $18.33B | 0.07% |
SCHA | 43.31% | $16.91B | 0.04% |
GSSC | 43.11% | $538.65M | 0.2% |
PSC | 43.09% | $811.78M | 0.38% |
KJAN | 42.94% | $305.13M | 0.79% |
FNY | 42.92% | $370.03M | 0.7% |
Yahoo
-- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology (ESPE-ESE); 32nd annual European Congress on Obesity (ECO); and the 2025 annual meeting of the Pediatric Endocrine Society (PES 2025) -- BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-sta
Yahoo
Despite inventory challenges, Rhythm Pharmaceuticals Inc (RYTM) reports robust growth in patient numbers and maintains a solid cash position to support future operations.
SeekingAlpha
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ETCompany ParticipantsDavid Connolly - IRDavid Meeker -...
SeekingAlpha
The following slide deck was published by Rhythm Pharmaceuticals, Inc.
Yahoo
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -17.39% and 18.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
-- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 -- -- Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on tra
Current Value
$59.921 Year Return
Current Value
$59.921 Year Return